Biochemically stabilized HIV-1 Env trimer vaccine
AssigneesBeth Israel Deaconess Medical Center, Inc., Children's Medical Center Corporation
InventorsStephen C. Harrison, Bing Chen, Dan Barouch, Joseph P. Nkolola, Michael Scott Seaman
Life of this patent
Estimating the term…
Abstract
Stabilized trimers of a clade A strain and a clade C strain of HIV-1 are provided. Broadly neutralizing antisera against HIV-1, methods of making broadly neutralizing antisera against HIV-1, broadly neutralizing vaccines against HIV-1, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided.
Claims19
A method of inducing an immune response against HIV in a subject, the method comprising:
- a. administering to the subject a first immunogenic composition comprising an immunologically effective amount of a gp140 polypeptide trimer, wherein the trimer comprises three identical polypeptide sequences, each polypeptide sequence comprising an amino acid sequence that is at least 98% identical to residues 30-708 of SEQ ID NO:2;
- and
- b. subsequently administering to the subject a second immunogenic composition comprising an immunologically effective amount of a gp140 polypeptide trimer, wherein the trimer comprises three identical polypeptide sequences, each polypeptide sequence comprising an amino acid sequence that is at least 98% identical to residues 30-708 of SEQ ID NO:2;
- wherein the first and/or second immunogenic composition further comprise an adjuvant.
A method of inducing an immune response against HIV in a subject, the method comprising:
- a. administering to the subject a first immunogenic composition comprising a nucleic acid sequence encoding one or more HIV-1 envelope polypeptide(s);
- and
- b. subsequently administering to the subject a second immunogenic composition comprising an immunologically effective amount of a gp140 polypeptide trimer, wherein the trimer comprises three identical polypeptide sequences, each polypeptide sequence comprising an amino acid sequence that is at least 98% identical to residues 30-708 of SEQ ID NO:2.
Dependencies are inferred from the claim text.